{
  "abstract": "Up to 40% of patients with estrogen receptor positive breast cancer will experience relapse, either while on endocrine therapy (ET) or after ET is completed. A major contributor to ET failure is the presence of ET-insensitive cell populations within tumors. Here, we developed an analytical pipeline to systematically identify and target these populations by integrating single-cell RNA sequencing of ER+ tumors from the FELINE clinical trial with functional validation in a panel of patient-derived xenograft organoid models. We found that ET-insensitive cells are detected in all tumors regardless of clinical response and exhibit higher transcriptional heterogeneity than ET-sensitive populations. Using our pipeline, we identified and validated new therapeutic options that target patient-specific and shared ET-insensitive populations. Our integrated workflow provides a robust platform for identifying and targeting ET-insensitive cells and offers a translational framework to develop precision medicine approaches to improve outcome in breast cancer patients.",
  "abstract_shown": true,
  "affiliations": [
    "University of Illinois College of Medicine"
  ],
  "article_type": "New results",
  "arxiv": null,
  "author_total": 13,
  "authors": [
    {
      "name": "S. Semina"
    },
    {
      "name": "R. J. Huggins"
    },
    {
      "name": "H. Zhao"
    },
    {
      "name": "K. Yanagihara"
    },
    {
      "name": "M. Sheinin"
    },
    {
      "name": "V. Macias"
    },
    {
      "name": "F. Alani"
    },
    {
      "name": "L. Feferman"
    },
    {
      "name": "A. A. Kajdacsy-Balla"
    },
    {
      "name": "D. Tonetti"
    },
    {
      "name": "K. Hoskins"
    },
    {
      "name": "J. Frasor"
    },
    {
      "affs": [
        0
      ],
      "name": "J. L. Coloff"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8p6wcqa79tysn.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.09.10.750719",
  "fulltext_url": "https://www.biorxiv.org/content/10.64898/2026.09.10.750719v1.full",
  "id": "8p6wcqa79tysn",
  "issns": [],
  "landing_url": "https://www.biorxiv.org/content/10.64898/2026.09.10.750719v1",
  "language": null,
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "biorxiv",
      "cancer biology"
    ],
    [
      "openalex",
      "1306|Breast Cancer Treatment Studies"
    ]
  ],
  "openalex": "W7213276095",
  "pdf_url": "https://www.biorxiv.org/content/10.64898/2026.09.10.750719v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-10",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/8p6wcqa79tysn.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:22:38Z",
      "native_id": "10.64898/2026.09.10.750719",
      "source": "biorxiv",
      "url": "https://www.biorxiv.org/content/10.64898/2026.09.10.750719v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "biorxiv:cancer biology",
      "subfield": "oncology"
    }
  ],
  "title": "Integrative pipeline to profile and target endocrine therapy-insensitive cell populations in ER+ breast cancer",
  "title_text": "Integrative pipeline to profile and target endocrine therapy-insensitive cell populations in ER+ breast cancer",
  "type": "preprint",
  "updated_at": "2026-10-30T12:22:38Z",
  "url": "https://research.draconitic.com/paper/8p6wcqa79tysn",
  "venue": "bioRxiv",
  "versions": []
}